ACR Meeting Abstracts
Abstract Number: 712 • ACR/ARHP Annual Meeting 2015
Mary Gibson1, MinJae Lee2, Michael M. Ward3, Lianne S. Gensler4, Matthew A. Brown5, Shervin Assassi6, Colton Pence1, Laura A. Diekman7, Mohammad H. Rahbar8, Michael H. Weisman9 and John D. Reveille1, 1Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, 2Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, Houston, TX, 3NIH/NIAMS, Bethesda, MD, 4Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 5The University of Queensland Diamantina Institute, Brisbane, Australia, 6Rheumatology, University of Texas Medical School at Houston, Houston, TX, 7Rheumatology, University of Texas Medical School, Houston, TX, 8The University of Texas Health Science Center at Houston, Houston, TX, 9Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: TNF-α inhibitor therapy is recommended by ASAS/EULAR guidelines for ankylosing spondylitis (AS) patients with moderate-to-high disease activity despite inadequate response to NSAIDs in addition…